SUNPHARMA Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > sunpharma

Technical Analysis

Technical Strength: 3.3 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 41.3. According to RSI analysis, sunpharma is technically weak. 1.0 SUNPHARMA RSI Chart
MACD (?) MACD: -5.59 and Signal Line: -3.05. According to MACD analysis, sunpharma is technically weak. 2.0 SUNPHARMA MACD Chart
Simple Moving Average (?) 20-day simple moving average just got below it's 50-day simple moving average which is a negative signal. According to simple moving average analysis, sunpharma is facing resistance at 509 and support level is at 458.4225. 2.0 SUNPHARMA Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, sunpharma is facing resistance at 508 and support level is at 473.2079. 7.0 SUNPHARMA Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.0292. According to bollinger bands, sunpharma has recently hit the lower band which is a negative signal. 2.0 SUNPHARMA Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is below all levels. Resistance levels are 505.5765, 516.875 and 528.1735. Support is at 469.0. 7.0 SUNPHARMA Fibonacci Retracement Chart
Average True Range (?) ATR: 17.9 NA SUNPHARMA Average True Range Chart
Average Directional Index (?) ADX is 13.5 which means SUNPHARMA is in a trading range and there is no trend. NA SUNPHARMA Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
September 25, 2020
Open Price 496.0
High Price 496.0
Low Price 483.85
Close Price 489.65
Absolute Change 3.85
Percentage Change 0.793%
Weekly Change -6.44%
Monthly Change -11.9%
Yearly Change 19.6%
52-week high 564.75
52-week low 312.0
Corporate Actions
ExDate Purpose
August 19, 2020 AGM/DIV - RE 1 PER SH
February 17, 2020 INT DIV-RS 3 PER SH
August 20, 2019 AGM/DIV-RS 2.75 PER SH
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.594
Confidence in Beta2.18%
Market Capital Rs. 101405.0 Cr
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 25 September 2020: Deliverable Quantity:2.67e+06 NA SUNPHARMA Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 25 September 2020: Daily Volatility:0.4566 NA SUNPHARMA Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 25 September 2020: PCR_OI:0.601 PCR:0.51 NA SUNPHARMA PCR Chart
Option Pain (?) 25 September 2020: Max Pain:500.0 NA SUNPHARMA Option Pain Chart
Premium (?) 25 September 2020 Premium: 2.05 Futures OI:32606000.0 NA SUNPHARMA Premium Chart
Option_MAX_OI (?) 25 September 2020: Price:489.65 Put with maximum OI:450.0 Call with maximum OI:600.0 NA SUNPHARMA Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
October 29, 2020 491.7 32606000.0 8551.0 8551.0 489.65
November 26, 2020 493.55 176400.0 161.0 161.0 489.65
December 31, 2020 499.1 4200.0 3.0 3.0 489.65


July 29, 2020 Book Closure Sun Pharmaceutical Industries Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 21-Aug-2020 to 27-Aug-2020 (both days inclusive) for the purpose of holding of Annual General Meeting and payment of final Dividend.
September 12, 2018 News Clarification The Exchange has sought clarification from the Company with respect to news item captioned-Sun Pharma Mohali plant on FDA radar In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.
See all Announcements

Board Meetings

Date Meeting Date Purpose
July 23, 2020 July 31, 2020 Financial Results To consider and approve the Unaudited Standalone and Consolidated Financial Results financial results for the quarter ended Jun 30, 2020
May 19, 2020 May 27, 2020 Financial Results/Dividend To consider and approve Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2020 and to consider recommendation of final dividend for the year ended March 31, 2020 subject to the approval of the shareholders at the ensuing Annual General Meeting.
See all Board Meetings

Get Clearnifty's Android App.

Get clearnifty on Google Play
Get clearnifty on Google Play